Abstract Number: 2912 • 2016 ACR/ARHP Annual Meeting
Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)
Background/Purpose: PROMIS-29 is a generic health-related quality of life (HRQoL) instrument that was developed as part of the NIH Patient Reported Outcomes (PROs) Roadmap. Our…Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…Abstract Number: 3249 • 2016 ACR/ARHP Annual Meeting
Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease
Background/Purpose: While chronic cough occurs in the majority of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD),1 its impact on quality of life has not…Abstract Number: 1236 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs
Background/Purpose: Interstitial lung disease (ILD) is commonly associated with rheumatoid arthritis (RA) and can have significant morbidity and mortality. The objective was to calculate the…Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting
Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…Abstract Number: 1501 • 2016 ACR/ARHP Annual Meeting
The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic disease with a known association with lymphoma and interstitial lung disease (ILD). ILD is a frequent extraarticular manifestation…Abstract Number: 2962 • 2015 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
Background/Purpose: Treatment with cyclophosphamide (CYC) for 12 months stabilizes lung function parameters and improves respiratory symptoms of patients with systemic sclerosis and diffuse interstitial lung…Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…Abstract Number: 2611 • 2015 ACR/ARHP Annual Meeting
Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)
Background/Purpose : Interstitial pneumonia (IP) is one of the most critical complications in rheumatoid arthritis (RA). Severe IP is developed in zymosan-treated SKG mice, and…Abstract Number: 2375 • 2015 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermtomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Interstitial Lung Disease…Abstract Number: 2362 • 2015 ACR/ARHP Annual Meeting
Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response
Background/Purpose: Rituximab (RIX) has successfully been used for the treatment of severe Jo-1 antibody-associated antisynthetase syndrome (Jo-1 ASS). The aim of this retrospective study was…Abstract Number: 2360 • 2015 ACR/ARHP Annual Meeting
The Effectiveness of Tacrolimus in Patients with Interstitial Lung Disease Secondary to Autoimmune Disease
Background/Purpose: Interstitial lung disease (ILD) secondary to connective tissue disease (CTD) is most commonly seen in systemic sclerosis followed by polymyositis and dermatomyositis. Anti-synthetase syndrome…Abstract Number: 1897 • 2015 ACR/ARHP Annual Meeting
Fragmented Qrs Patterns Do Not Correlate with the Degree of Lung and Skin Involvement in Patients with Systemic Sclerosis
Background/Purpose: Cardiac involvement is a common subclinical feature of systemic sclerosis (SSc) and results from the widespread fibrosis observed during disease course. Fragmented QRS (fQRS)…Abstract Number: 1882 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Patients with diffuse cutaneous systemic sclerosis (dcSSc) have…Abstract Number: 1590 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis
Background/Purpose:Interstitial lung disease (ILD) is a severe rheumatoid arthritis manifestation with a median survival of 2.6 years. Worst survival has been associated to usual interstitial…